Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/16/09

Novello S et al. – The safety profile and time-to-event analyses, albeit relatively low response rate of 2%, suggest single-agent sunitinib on a CDD schedule may be a potential therapeutic agent for patients with advanced, refractory NSCLC.

Methods

Examination of activity of sunitinib on continuous daily dosing (CDD) schedule in open-label, multicentre phase II study in patients with previously treated, advanced NSCLC
Patients > 18 years with stage IIIB/IV NSCLC after failure with platinum-based chemotherapy, received sunitinib 37.5 mg per day. The primary end point was objective response
Primary end point objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), 1-year survival rate, and safety

Results

Of 47 patients receiving sunitinib, 1 patient achieved confirmed partial response (ORR 2.1% (95% confidence interval (CI) 0.1, 11.3)) and 11 (23.4%) had stable disease (SD) 8 weeks
Five patients had SD> 6 mos
Median PFS was 11.9 weeks and median OS 37.1 weeks
1-y survival probability 38.4%
Treatment generally well tolerated

<< Previous
Prognostic significance of alterations in KRAS isoforms...

Next >>
Prolonged facial edema is an indicator of poor prognosis in...